Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Price Target Raised to $9.00 at HC Wainwright

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) had its price target lifted by research analysts at HC Wainwright from $7.00 to $9.00 in a report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Several other equities research analysts have also commented on the company. Craig Hallum started coverage on Lineage Cell Therapeutics in a research report on Tuesday, August 20th. They issued a “buy” rating and a $4.00 price objective on the stock. D. Boral Capital reduced their price target on Lineage Cell Therapeutics from $3.00 to $2.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th.

Lineage Cell Therapeutics Trading Down 7.1 %

NYSEAMERICAN LCTX opened at $0.55 on Wednesday. The stock has a market cap of $103.26 million, a PE ratio of -4.56 and a beta of 1.16. Lineage Cell Therapeutics has a one year low of $0.50 and a one year high of $1.61.

Institutional Trading of Lineage Cell Therapeutics

Hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in Lineage Cell Therapeutics during the 3rd quarter worth approximately $46,000. XTX Topco Ltd purchased a new stake in shares of Lineage Cell Therapeutics during the second quarter valued at $61,000. GSA Capital Partners LLP purchased a new position in Lineage Cell Therapeutics during the 3rd quarter valued at approximately $84,000. Rhumbline Advisers raised its position in shares of Lineage Cell Therapeutics by 15.1% in the 2nd quarter. Rhumbline Advisers now owns 132,491 shares of the company’s stock worth $132,000 after acquiring an additional 17,411 shares in the last quarter. Finally, Barclays PLC grew its holdings in Lineage Cell Therapeutics by 311.3% during the third quarter. Barclays PLC now owns 211,300 shares of the company’s stock worth $192,000 after acquiring an additional 159,924 shares during the period. Institutional investors and hedge funds own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.